Literature DB >> 16911342

Gamma-hydroxybutyrate--a drug of abuse.

K R Drasbek1, J Christensen, K Jensen.   

Abstract

Gamma-hydroxybutyrate (GHB) is a drug of abuse that causes euphoria, anxiolysis, and hypnosis. The recent rise in the recreational intake of GHB, as well as its association with 'drug rape', has turned the attention to GHB in acute hospital settings. Acutely admitted GHB intoxicated patients may display various levels of sedation or coma, but may also show paradoxical agitation, combativeness, or self-injurious behaviors. The symptoms can be nonspecific and the definite diagnosis therefore normally relies on the detection of GHB in blood or body fluids, which is an analysis that may not be promptly available. As a basis for understanding the clinical features of GHB intoxication and abuse, we here review the pharmacological and neurophysiological knowledge about GHB, which stems from decades of clinical and basic GHB research. In addition, we discuss the latest discoveries in the quest for distinct GHB receptors in the brain, and their possible implications for future therapies of GHB abuse.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16911342     DOI: 10.1111/j.1600-0404.2006.00712.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  18 in total

1.  Effect of γ-hydroxybutyrate (GHB) on driving as measured by a driving simulator.

Authors:  Evangelia Liakoni; Delia A Dempsey; Matthew Meyers; Nancy G Murphy; Dary Fiorentino; Christopher Havel; Christine Haller; Neal L Benowitz
Journal:  Psychopharmacology (Berl)       Date:  2018-09-19       Impact factor: 4.530

2.  New synthesis and tritium labeling of a selective ligand for studying high-affinity γ-hydroxybutyrate (GHB) binding sites.

Authors:  Stine B Vogensen; Aleš Marek; Tina Bay; Petrine Wellendorph; Jan Kehler; Christoffer Bundgaard; Bente Frølund; Martin H F Pedersen; Rasmus P Clausen
Journal:  J Med Chem       Date:  2013-10-04       Impact factor: 7.446

Review 3.  Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.

Authors:  Rama M Kamal; Martijn S van Noorden; Wim Wannet; Harmen Beurmanjer; Boukje A G Dijkstra; Arnt Schellekens
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

4.  A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for γ-Hydroxybutyric Acid Overdose.

Authors:  Nisha Vijay; Bridget L Morse; Marilyn E Morris
Journal:  Pharm Res       Date:  2014-12-06       Impact factor: 4.200

5.  Driving under the influence of gamma-hydroxybutyrate (GHB).

Authors:  Alan Wayne Jones; Anita Holmgren; Fredrik C Kugelberg
Journal:  Forensic Sci Med Pathol       Date:  2008-05-14       Impact factor: 2.007

6.  Forensic toxicology findings in deaths involving gamma-hydroxybutyrate.

Authors:  Fredrik C Kugelberg; Anita Holmgren; Arne Eklund; Alan Wayne Jones
Journal:  Int J Legal Med       Date:  2008-12-02       Impact factor: 2.686

7.  Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology.

Authors:  I Knerr; P L Pearl; T Bottiglieri; O Carter Snead; C Jakobs; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

8.  Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients.

Authors:  Ina Knerr; K Michael Gibson; Cornelis Jakobs; Phillip L Pearl
Journal:  CNS Spectr       Date:  2008-07       Impact factor: 3.790

9.  Pharmacokinetic interaction between the flavonoid luteolin and gamma-hydroxybutyrate in rats: potential involvement of monocarboxylate transporters.

Authors:  Xiaodong Wang; Qi Wang; Marilyn E Morris
Journal:  AAPS J       Date:  2008-01-30       Impact factor: 4.009

10.  Liquid ecstasy - a significant drug problem.

Authors:  Hilke Andresen; Thomas Stimpfl; Nadine Sprys; Tino Schnitgerhans; Alexander Müller
Journal:  Dtsch Arztebl Int       Date:  2008-09-05       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.